Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 363

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 363
---
 or other distributions on Common or Preferred Stock; (viii) incur any indebtedness in excess of $1 million (other than ordinary trade indebtedness); (ix) increase or decrease the number
of Directors on the Board; or (x) enter into any related party transactions other than changes in the compensation of the Company’s executive officers.

Dividends: The holders of Preferred Stock will not be entitled to dividends with respect to such shares, provided however that if the Board of
Directors declares any dividends, holders of Preferred Stock will first receive at least an amount equal to the sum of (i) any declared but unpaid dividends on the applicable series of Preferred Stock plus (ii) a pro rata share of any
dividends to be paid on other classes and series of the Company’s stock.

Liquidation Preference: In the event of any liquidation,
dissolution or winding-up of the Company, the liquidation preference is as follows:

First: Series C preferred stockholders would be entitled to receive the greater of: (i) $1.50 per share (adjusted for any
stock dividends, combinations or splits or similar transactions with respect to such shares), or (ii) the amount that would be received if the shares of Series C preferred stock were converted to common stock (“Series C Preference
Amount”). Upon payment in full of the Series C Preference Amount, the holders of Series C preferred stock, shall not receive any additional payments from the Company. In the event the funds or assets are insufficient to pay in full the Series
C Preference Amount, as described above, then all funds or assets available for shall be paid to the holders of Series C Stock pro rata based on the full Series C Preference Amount to which they are entitled.

Second: Series B preferred stockholders would be entitled to receive the greater of: (i) $3.00 per share (adjusted for any
stock dividends, combinations or splits or similar transactions with respect to such shares), or (ii) the amount that would be received if the Series B Preferred were converted to Common Stock (“Series B Preference Amount”). In the
event the funds or assets are insufficient to pay in full the Series B Preference Amount, as described above, then all funds or assets available for shall be paid to the holders of Series B Stock pro rata based on the full Series C Preference Amount
to which they are entitled.

F-24

LB Pharmaceuticals Inc

Notes to Financial Statements

Third: Series A preferred stockholders will be entitled to receive the